Axillary lymph node dissection for breast cancer: A decision analysis of T1 lesions

Annals of Surgical Oncology

Volumn 5, Issue 2, 1998, Pages 131-139

  Velanovich, Vie ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Adjuvant chemotherapy; Axillary lymph node dissection; Breast cancer; Decision analysis

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; HUMAN; LIFE EXPECTANCY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT INDICATION;

AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LIFE EXPECTANCY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MASTECTOMY, SIMPLE; NEOPLASM STAGING; PROBABILITY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032430902     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303846     Document Type: Article

References (41)

1. Ruffin WK, Stacey-Clear A, Younger J, Hoover HC. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245-51.
2. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-8.
3. Deckers PJ. Axillary dissection in breast cancer: When, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217-9.
4. Davidson NE, Abeloff MD. Adjuvant therapy of breast cancer. World J Surg 1994;18:112-6.
5. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagani P. Axillary lymph node dissection for T1a breast carcinoma: Is it indicated? Cancer 1994;73:664-7.
6. Reger V, Beito G, Jolly PC. Factors affecting the incidence of lymph node metastases in small cancers of the breast. Am J Surg 1989;157:501-2.
7. Haffty BG, McKhann C, Beinfield M, Fischer D, Fischer JJ. Breast conservation therapy without axillary dissection: A rationale treatment strategy in selected patients. Arch Surg 1993;128:1315-9.
8. Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N, Baker RR. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-44.
9. Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996;183:185-9.
10. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg 1993;217:207-25.
11. Eberlein TJ. Current management of carcinoma of the breast. Ann Surg 1994;220:121-36.
12. Hortobagyi GN, Bazdur AU. Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy. CA Cancer J Clin 1995;45:199-226.
13. Clark GM, Mathieu M-C, Owens MA, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992;10:428-32.
14. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340: 1120-4.
15. Davidoff AM, Herndon JE II, Glover NS, Kerns BM, Pence JC, Iglehart D, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1994;110: 259-64.
16. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72;3641-7.
17. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
18. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BM, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219:332-41.
19. Pujol P, Maudelonde T, Daures J-P, Rouanet P, Brouillet J-P, Pujol H, Rochefort H. A prospective study of the prognostic value of cathespin D levels in breast cancer cytosol. Cancer 1993;71:2006-12.
20. Gasparini G, Wiedner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
21. Beck R, Kassirer JP, Pauker SG. Convenient approximation of life expectancy (the DEALE): Validation of the method. Am J Med 1982;73:883-8.
22. Beck R, Pauker SG, Gottlieb E, Klein J, Kassirer JP. Convenient approximation of life expectancy (the DEALE): utility in medical decision making. Am J Med 1982;73:889-97.
23. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia: WB Saunders, 1980.
24. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
25. Horsley JS, Styblo T. Lymphedema in the postmastectomy patient. In: Bland KI, Copeland EM III, eds. The breast. Philadelphia: WB Saunders, 1991:701-6.
26. Wells SA Jr, Young VL, Andriole DA. Atlas of breast surgery. St. Louis: Mosby, 1994:79-85.
27. Chadha M, Chabon AB, Friedman P, Vikram B. Predictors of axillary lymph node metastasis in patients with T1 breast cancer: a multivariate analysis. Cancer 1994;73:350-3.
28. Dowlatshahi K, Snider HC, Kim R. Axillary node status in non-palpable breast cancer. Ann Surg Oncol 1995;2:424-8.
29. Anderson MJ, Kramer BS. Adjuvant systemic therapy for early stage breast cancer. In: Bland KI, Copeland EM III, eds. The breast. Philadelphia: WB Saunders, 1991:817-42.
30. Wood WC. Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 1994;18:39-44.
31. Fisher B, Redmond C, Dimitrov N, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
32. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-8.
33. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
34. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An inter-group study. N Engl J Med 1989;320:485-90.
35. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992; 326:1756-61.
36. Muss HB, Thor AD, Berry DA, et al. c-erb-B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
37. Klijn JGM, Berns EMJJ, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 1993;19(Suppl B):45-63.
38. Velanovich V. Biologic tumor markers, lymph node status, and decisions about adjuvant chemotherapy for breast cancer. Presented at the 64th Annual Scientific Meeting of the Southeastern Surgical Congress, Tampa, FL, February 5, 1996.
39. Christensen SB, Jansson C. Axillary biopsy compared with dissection in the staging of lymph nodes in operable breast cancer: A randomized trial. Eur J Surg 1993;159:159-62.
40. Hadjiminas DJ, Burke M. Intraoperative assessment of nodal status in the selection in the selection of patients with breast cancer for axillary clearance. Br J Surg 1994;81:1615-6.
41. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Aim Surg 1995;222:394-401.